What’s next for boards in the UK life sciences industry?

Life sciences organisations currently have great potential to thrive in the UK however, they are also facing significant challenges which, if not managed correctly, will limit this opportunity. Hear from industry experts to learn what boards must consider to successfully govern in this post-Covid era.

With life sciences companies facing an aging population, increasing pricing pressures, cybersecurity risks, changing sanction regimes, ESG concerns and mounting pressure to innovate to keep up with the industry’s rapid transformation, clear strategic direction is more important than ever.

This podcast brings together a panel of experts to discuss the main sector challenges, discuss which should be prioritised, and lend their advice to boards.

Key themes discussed include:

  • Key priorities for boards in the life sciences industry as they transition to the future of healthcare
  • Harnessing opportunities from rapid digitalisation and tech disruption
  • Building resilience in an era of rapid transformation
  • Ideal skill sets and composition of life sciences company boards
  • How boards in pharma and life sciences are integrating ESG and building trust with stakeholders

The podcast guests are:

  • Dr Richard Torbett, CEO of The Association of The British Pharmaceutical Industry (ABPI)  
  • Nigel Layton, Global life sciences and pharma lead
  • Stuart Paynter, CFO at Oxford Biomedica
  • Seyda Atadan Memis, General Manager UK and Ireland at Takeda
  • Hosted by Gavin Hinks of Board Agenda

Stream here

Board Agenda - What’s next for boards in the UK pharma and life sciences industry